Skip to main content
Equibles
ZURA logo

ZURA · Zura Bio Ltd

Track ZURA — free

Use ZURA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZURA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.15 +0.19 (+4.80%) At close · Oct 7
Russell 2000 member Rebalance outlook locked
Market Cap
$377.57M
Shares
95.83M
Volume · Oct 7 2.08M Avg daily vol (3M) 1.4M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.96 Open$3.97 Day$3.82–4.06 52W close$3.21–7.04 Avg vol 30d1.8M Short int9.3M · 9.7% float · 6.4d Short vol63% DataMar 2023–Oct 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-5.0%
Trailing year
Short interest
9.7%
Latest settlement · 6.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −26%
below
Price vs 50-day avg −25%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 20%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −35%
trailing
6-month return −30%
trailing
YTD return −24%
this year
Relative strength −42%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Death cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.75% of float · ▼ -15.8% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
97 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Poor
EPS growth −77%
Y/Y
Free cash flow $-64.9M
Quant / Vol
risk profile
Very High
Volatility 80%
annualized · 1-yr
Max drawdown −52%
past year
ATR 8.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) Death cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+3% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.75% of float · ▼ -15.8% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
97 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 20% Range high $7
vs 200-day avg -26% vs 50-day avg -25% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZURA
Zura Bio Ltd
this stock
$377.57M -24.4% — — 9.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +10.8% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.3% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $78.44B +535.7% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
97
% held
76.3%
Net QoQ
+6.7M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
16
View
Short & Settlement
Short Interest Falling
Shares short
9.3M
Days to cover
6.4d
Change
-1.8M sh
View
Short Volume
Short vol %
63%
As of
Oct 7, 2026
Short Total
View
Fails to Deliver
FTD shares
18.3K
Value
$104.3K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
40.7%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-68.7M
EPS diluted
$-1.06
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 17, 2026
This year
21
View
Proposed Sales
Value
$287.7K
Shares
50.0K
Filed
Aug 18, 2026
View
Exempt Offerings
Offering
$112.5M
Filed
May 6, 2024
View

Performance

5D 20D 120D MTD YTD
ZURA -1.0% -35.4% -30.4% -4.8% -24.4%
SPY +2.0% +1.7% +11.3% +2.2% +14.3%
vs SPY -3.0% -37.1% -41.7% -7.0% -38.7%
Key facts CIK 1855644 CUSIP G9TY5A101 13F (30d) 2 filings 2 filers Visit website Investor relations